Edsmyr F, Andersson L, Esposti P L, Littbrand B, Nilsson B
Radiother Oncol. 1985 Nov;4(3):197-203. doi: 10.1016/s0167-8140(85)80084-0.
In a clinical trial 168 patients with carcinoma of the bladder, T2-T4, were randomized to one of two treatments; 1 Gy 3 times a day to a total of 84 Gy or 2 Gy once a day to a total of 64 Gy. Local eradication of the tumour in the bladder cystoscopically and cytologically at 6 months after completion of treatment and patient survival were analyzed. The results favoured significantly the patients treated with 84 Gy. All patients were followed 5-9 years. The survival was significantly improved in patients with T3 lesions treated with 84 Gy (p less than 0.01). Complications in the bowel requiring surgical treatment were not significantly different between the two groups of patients. The results indicate a therapeutic gain by hyperfractionated radiotherapy in comparison to conventional fractionated radiotherapy.
在一项临床试验中,168例T2 - T4期膀胱癌患者被随机分为两种治疗方案之一:每天3次,每次1 Gy,总剂量84 Gy;或每天1次,每次2 Gy,总剂量64 Gy。在治疗完成后6个月,通过膀胱镜检查和细胞学检查分析膀胱肿瘤的局部根除情况以及患者生存率。结果显著有利于接受84 Gy治疗的患者。所有患者均随访5 - 9年。接受84 Gy治疗的T3期病变患者生存率显著提高(p小于0.01)。两组患者中需要手术治疗的肠道并发症无显著差异。结果表明,与传统分割放疗相比,超分割放疗有治疗优势。